Natus Medical (NASDAQ:BABY) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Tuesday, October 24th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $46.50.

Natus Medical (NASDAQ:BABY) traded down $0.30 during trading on Friday, hitting $37.60. The stock had a trading volume of 415,693 shares, compared to its average volume of 359,540. The stock has a market cap of $1,180.74, a PE ratio of 24.45 and a beta of 0.84. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. Natus Medical has a 12 month low of $31.65 and a 12 month high of $43.60.

Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.02. The company had revenue of $122.60 million during the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The business’s revenue was up 34.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.39 EPS. equities analysts forecast that Natus Medical will post 1.74 EPS for the current year.

In related news, Director William M. Moore sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the sale, the vice president now directly owns 141,414 shares in the company, valued at $6,068,074.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,042 shares of company stock worth $902,266. Corporate insiders own 5.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Alps Advisors Inc. increased its position in Natus Medical by 0.3% in the second quarter. Alps Advisors Inc. now owns 12,906 shares of the medical equipment provider’s stock worth $481,000 after buying an additional 33 shares during the period. Pinebridge Investments L.P. increased its position in Natus Medical by 1.7% in the second quarter. Pinebridge Investments L.P. now owns 4,359 shares of the medical equipment provider’s stock worth $163,000 after buying an additional 71 shares during the period. Arizona State Retirement System increased its position in Natus Medical by 1.2% in the second quarter. Arizona State Retirement System now owns 17,306 shares of the medical equipment provider’s stock worth $646,000 after buying an additional 200 shares during the period. Municipal Employees Retirement System of Michigan increased its position in Natus Medical by 3.2% in the second quarter. Municipal Employees Retirement System of Michigan now owns 7,760 shares of the medical equipment provider’s stock worth $289,000 after buying an additional 240 shares during the period. Finally, Texas Permanent School Fund increased its position in Natus Medical by 1.5% in the second quarter. Texas Permanent School Fund now owns 24,160 shares of the medical equipment provider’s stock worth $901,000 after buying an additional 364 shares during the period. 94.39% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Natus Medical (BABY) Downgraded by BidaskClub to “Sell”” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/09/natus-medical-baby-downgraded-by-bidaskclub-to-sell.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.